Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK0804 Add-on Therapy in Myelofibrosis With Suboptimal Response to Ruxolitinib
NCT05423691Phase 1Recruiting
- Start
- Dec 2022
- Primary completion
- Apr 2027
- Modality
- Regulatory T Cells (Tregs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CK0804 in myelofibrosis (MF). Primary endpoint: Treatment Limiting Toxicity at 28 days. Started Dec 2022; status: recruiting.
02
Drugs
CK0804
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05423691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05423691.